Main Article Content
Objective: To study the eﬃcacy and safety of ulipristal acetate in the medical management of ﬁbroid uterus.
Materials and methods: A total of 36 cases of ﬁbroid uterus aged between 25 to 50 years, who had completed family were assigned to receive ulipristal acetate 5 mg once daily for three months. Patients were followed up at end of three month of therapy, and then one month after treatment was stopped. The parameters evaluated were menstrual blood loss (MBL), haemoglobin level, volume of the uterus and ﬁbroid, pain by numerical rating scale and the endometrial thickness. These parameters were measured at start of therapy (baseline), after three months of treatment and then one month after treatment was stopped. The side eﬀects and patient acceptability of drug ulipristal acetate were assessed.
Results: Treatment with ulipristal acetate results in signiﬁcant reduction of MBL, haemoglobin level, volume of the uterus and ﬁbroid, pain. There was no statistically signiﬁcant change seen in endometrial thickness (ET) with use of ulipristal acetate. Adverse eﬀects reported were amenorrhoea, hot ﬂushes, hypomenorrhoea and spotting. One case of mild liver injury was reported.
Conclusion: Ulipristal acetate is an eﬀective therapeutic option for the medical management of ﬁbroid uterus in properly selected cases. During the treatment period liver function test should be monitored.
Keywords: Menstrual blood loss; Haemoglobin; Endometrial thickness